Using secosteroids to treat skin cancer caused by UVB exposure
Official title: CYP11A1-derived secosteroids as therapeutic agents in UVB induced skin cancer
Funded at Birmingham VA Medical Center · NIH-11010771 · Data updated 2026-11-12
This study is looking at a new treatment for skin cancer caused by UVB rays, using special compounds that might help slow down cancer growth and heal the skin, so patients can have better options for their care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Birmingham VA Medical Center NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | January 1, 2019 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX004293-07 |
| Project ID | NIH-11010771 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals diagnosed with skin cancer related to UVB exposure.
✕Less likely to help
Patients with skin cancer not related to UVB exposure or those with other unrelated skin conditions may not benefit from this research.
What this research studies
This research investigates the potential of secosteroids derived from CYP11A1 as therapeutic agents for skin cancer that develops due to UVB radiation. The approach focuses on understanding how these compounds can inhibit cancer cell growth and promote healing in affected skin. Patients may benefit from new treatment options that target the underlying mechanisms of UVB-induced skin cancer, potentially leading to improved outcomes. The methodology includes laboratory studies and possibly clinical trials to evaluate the effectiveness of these secosteroids in real-world scenarios.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options for patients suffering from UVB-induced skin cancer.
How similar studies have gone: While the use of secosteroids in this specific context is novel, there have been other studies exploring similar therapeutic approaches with promising results.
Where this research is happening
-
Birmingham VA Medical Center
Birmingham, United States Active
Researchers
- Principal investigator: Slominski, Andrzej T — Birmingham VA Medical Center
- Study coordinator: Slominski, Andrzej T
Related research
Other NIH-funded projects on the same topics.
-
Solar-powered sun protection for outdoor workers
A short project to help outdoor workers prevent skin cancer by using a tailored, story-based video and workplace actions to increase sun protection.
-
Skin cancer immunotherapy: better vaccines and biomarkers to help melanoma patients
A Yale-led program tests new drug combinations and biomarker tests to help people with advanced melanoma live longer and better, especially by guiding which treatment works best for them.
-
CivaDerm: a new four-day skin cancer radiation bandage
A new four‑day radiation bandage for non-melanoma skin cancer aims to treat facial and other areas without multiple clinic visits or big scars.
-
MOSAIC II: MAP Wound Matrix to speed graft readiness after non-melanoma skin cancer surgery
A randomized trial tests a moldable wound scaffold (MAP Wound Matrix) to speed healing and time to graft-ready skin after head and neck cancer surgeries in adults.
-
PASS: A family-based approach to sun safety in schools
A parent-focused program delivered through schools aims to help families protect children from sun exposure and reduce skin cancer risk.
-
Precision skin cancer risk feedback in community clinics
A multisite study tests giving adults personalized genetic risk information to boost sun protection and skin checks in low-resource primary care settings.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.